Blog Posts

Bausch & Lomb Becomes 35th Manufacturer to Impose Contract Pharmacy Restrictions, Policy Applies to All 340B Entities

Canadian drug manufacturer Bausch & Lomb announced contract pharmacy restrictions that apply to all 340B covered entity types.
Canadian drugmaker Bausch & Lomb announced last week that, beginning July 1, it will no longer offer 340B discounted products [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Alkermes Is 36th Drugmaker to Implement Contract Pharmacy Restrictions, Sanofi Tightens Policy

Pharmaceutical manufacturer Alkermes is the 36th drugmaker to implement 340B contract pharmacy restrictions.
Irish drugmaker Alkermes will implement, on July 22, 340B contract pharmacy restrictions. The Dublin-based manufacturer is the 36th drugmaker to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Michigan Lawmakers, Witnesses Spar Over 340B Contract Pharmacy Access Bill in Key Hearing

Ben Frederick, associate vice president of advocacy and government relations at Memorial Healthcare, testified in support of a 340B contract pharmacy access bill at a Michigan state house hearing.
Michigan state lawmakers and representatives for drugmakers, providers, and business groups debated a 340B contract pharmacy access bill during a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Mount Sinai Reports 340B Pharmacy Revenue Losses in Early 2024

New York City-based Mount Sinai Hospital reported significantly decreased 340B pharmacy revenue at the start of 2024.
A major New York City hospital reported that decreased 340B pharmacy revenue helped drive millions in year-over-year losses in one [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Reform Could Generate Federal Savings, Says Consulting Firm That Has Conducted 340B Studies for Pharma Friendly Groups

Avalere's Milena Sullivan told 340B Report that it's important to understand "the impact 340B reform could have on federal spending."
A federal legislative overhaul of the 340B program could provide Medicare savings for the federal government, according to a review [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Five Manufacturers Announce Refunds to 340B Providers

Five drug manufacturers will refund 340B covered entities for certain drug overcharges.
Five drugmakers have issued recent refund notices to 340B covered entities for drug overcharges. In letters posted on the website [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Key House Hearing Intensifies Debate on 340B’s Future Amid Multiple Major Reform Efforts

Rep. Morgan Griffith (R-VA), chairman of the House Energy and Commerce Oversight and Investigations Subcommittee, speaks at a hearing on June 4, 2024.
A House oversight hearing this week added to the growing debate over the 340B program’s future as federal lawmakers continue [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Minnesota Is Seventh State to Enact 340B Contract Pharmacy Law, State Also Expands Covered Entity Reporting

Minnesota Gov. Tim Walz (D) signed a law to prohibit drugmaker 340B contract pharmacy restrictions in the state.
Minnesota became the 7th state to enact a law to protect distribution of 340B drugs through contract pharmacies when the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

TPA Fees: Before You Sign on the Dotted Line

SPONSORED CONTENT

As the 340B program continues to grow in complexity, given the drug manufacturer restrictions, it is more important than ever for covered entities to have a firm grasp and understanding of the fees charged by their Third Party Adminisrators (TPAs) for their contract pharmacies. Whether it is

Read More »

New York Unlikely to Move 340B Contract Pharmacy, PBM Protections Bill in 2024, Sponsors Say

New York lawmakers are expected to leave Albany this week without passing legislation that would bar drug manufacturers' and pharmacy benefit managers' (PBMs) policies against covered entities and N.Y. pharmacies based on their 340B participation.
New York lawmakers are expected to leave Albany this week without passing legislation that would bar drug manufacturers and pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »